AR112902A1 - Receptores de células t restringidas a hla de clase ii contra ras mutado - Google Patents
Receptores de células t restringidas a hla de clase ii contra ras mutadoInfo
- Publication number
- AR112902A1 AR112902A1 ARP180102695A ARP180102695A AR112902A1 AR 112902 A1 AR112902 A1 AR 112902A1 AR P180102695 A ARP180102695 A AR P180102695A AR P180102695 A ARP180102695 A AR P180102695A AR 112902 A1 AR112902 A1 AR 112902A1
- Authority
- AR
- Argentina
- Prior art keywords
- restricted
- hla class
- cell receptors
- tcr
- mammal
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 102100030708 GTPase KRas Human genes 0.000 abstract 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Abstract
Se describe un receptor de células T aislado o purificado (TCR), en donde el TCR tiene especificidad antigénica para el homólogo de oncogén viral de sarcoma de rata Kirsten mutado (KRAS) presentado por una molécula de clase II de antígeno leucocitario humano (HLA). También se proporcionan proteínas y polipéptidos relacionados, así como ácidos nucleicos, vectores de expresión recombinantes, células huésped, poblaciones de células y composiciones farmacéuticas relacionados. También se describen métodos para detectar la presencia de cáncer en un mamífero y métodos para tratar o prevenir el cáncer en un mamífero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560930P | 2017-09-20 | 2017-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112902A1 true AR112902A1 (es) | 2019-12-26 |
Family
ID=63963389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102695A AR112902A1 (es) | 2017-09-20 | 2018-09-20 | Receptores de células t restringidas a hla de clase ii contra ras mutado |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11306132B2 (es) |
| EP (1) | EP3684799A1 (es) |
| JP (1) | JP7256794B2 (es) |
| KR (1) | KR20200051804A (es) |
| CN (1) | CN111201237A (es) |
| AR (1) | AR112902A1 (es) |
| AU (1) | AU2018335274A1 (es) |
| BR (1) | BR112020005469A2 (es) |
| CA (1) | CA3076339A1 (es) |
| CR (1) | CR20240019A (es) |
| EA (1) | EA202090652A1 (es) |
| IL (1) | IL273254B2 (es) |
| MA (1) | MA50180A (es) |
| MX (2) | MX2020003117A (es) |
| SG (1) | SG11202002425PA (es) |
| TW (1) | TWI825029B (es) |
| WO (1) | WO2019060349A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| CN113631172A (zh) * | 2019-01-25 | 2021-11-09 | 宾夕法尼亚大学理事会 | 用于靶向突变型ras的组合物和方法 |
| WO2021019476A1 (en) * | 2019-07-30 | 2021-02-04 | University Health Network | Methods of identifying t cell receptors |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| CA3164986A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| CA3170658A1 (en) * | 2020-02-19 | 2021-08-26 | Aelin Therapeutics | Molecules targeting mutant ras protein |
| KR20220143939A (ko) * | 2020-02-26 | 2022-10-25 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | G12v 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체 |
| US20230312672A1 (en) * | 2020-06-24 | 2023-10-05 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class i-restricted t cell receptors against cd20 |
| US20230272038A1 (en) * | 2020-07-13 | 2023-08-31 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class ii-restricted drb t cell receptors against ras with g12d mutation |
| AU2021309958A1 (en) * | 2020-07-16 | 2023-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class II-restricted DRB T cell receptors against RAS with G12V mutation |
| CN112300269B (zh) * | 2020-09-29 | 2022-12-09 | 中国科学院微生物研究所 | Kras突变特异性t细胞受体筛选及抗肿瘤用途 |
| WO2022111451A1 (zh) * | 2020-11-24 | 2022-06-02 | 上海吉倍生物技术有限公司 | Ras突变体表位肽及识别ras突变体的t细胞受体 |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| CN114835800B (zh) * | 2022-05-27 | 2023-10-13 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN117264043B (zh) * | 2022-06-14 | 2024-05-10 | 上海镔铁生物科技有限责任公司 | 靶向kras g12v突变多肽的t细胞受体及其用途 |
| WO2024072954A1 (en) * | 2022-09-29 | 2024-04-04 | Jerome Canady Research Institute for Advanced Biological and Technological Sciences | Cold atmopsheric plasma treated pan-cancer epitope peptide within the collagen type vi a-3 (col6a3) protein as cancer vaccine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP4074333A1 (en) * | 2014-10-02 | 2022-10-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation |
| WO2016085904A1 (en) * | 2014-11-26 | 2016-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mutated kras t cell receptors |
| WO2017015562A1 (en) * | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
| SG10201913868XA (en) | 2015-09-15 | 2020-03-30 | The United States Of America As Represented By The Secretary | T cell receptors recognizing hla-cw8 restricted mutated kras |
| WO2018026691A1 (en) | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t cell receptors |
-
2018
- 2018-09-19 WO PCT/US2018/051641 patent/WO2019060349A1/en active Application Filing
- 2018-09-19 JP JP2020516422A patent/JP7256794B2/ja active Active
- 2018-09-19 IL IL273254A patent/IL273254B2/en unknown
- 2018-09-19 MX MX2020003117A patent/MX2020003117A/es unknown
- 2018-09-19 EP EP18792591.2A patent/EP3684799A1/en active Pending
- 2018-09-19 SG SG11202002425PA patent/SG11202002425PA/en unknown
- 2018-09-19 CN CN201880060535.4A patent/CN111201237A/zh active Pending
- 2018-09-19 MA MA050180A patent/MA50180A/fr unknown
- 2018-09-19 BR BR112020005469-0A patent/BR112020005469A2/pt unknown
- 2018-09-19 AU AU2018335274A patent/AU2018335274A1/en active Pending
- 2018-09-19 CA CA3076339A patent/CA3076339A1/en active Pending
- 2018-09-19 EA EA202090652A patent/EA202090652A1/ru unknown
- 2018-09-19 KR KR1020207011112A patent/KR20200051804A/ko not_active Application Discontinuation
- 2018-09-19 US US16/135,231 patent/US11306132B2/en active Active
- 2018-09-19 CR CR20240019A patent/CR20240019A/es unknown
- 2018-09-20 TW TW107133221A patent/TWI825029B/zh active
- 2018-09-20 AR ARP180102695A patent/AR112902A1/es unknown
-
2020
- 2020-03-19 MX MX2024004610A patent/MX2024004610A/es unknown
-
2022
- 2022-03-11 US US17/692,787 patent/US20220204584A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220204584A1 (en) | 2022-06-30 |
| WO2019060349A1 (en) | 2019-03-28 |
| CR20240019A (es) | 2024-02-15 |
| US20190085046A1 (en) | 2019-03-21 |
| TW201920251A (zh) | 2019-06-01 |
| CN111201237A (zh) | 2020-05-26 |
| MX2020003117A (es) | 2020-08-20 |
| MA50180A (fr) | 2021-05-26 |
| JP2020534828A (ja) | 2020-12-03 |
| MX2024004610A (es) | 2024-04-30 |
| IL273254B1 (en) | 2024-05-01 |
| KR20200051804A (ko) | 2020-05-13 |
| CA3076339A1 (en) | 2019-03-28 |
| IL273254B2 (en) | 2024-09-01 |
| JP7256794B2 (ja) | 2023-04-12 |
| TWI825029B (zh) | 2023-12-11 |
| EP3684799A1 (en) | 2020-07-29 |
| US11306132B2 (en) | 2022-04-19 |
| IL273254A (en) | 2020-04-30 |
| EA202090652A1 (ru) | 2020-08-21 |
| SG11202002425PA (en) | 2020-04-29 |
| BR112020005469A2 (pt) | 2020-09-29 |
| AU2018335274A1 (en) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112902A1 (es) | Receptores de células t restringidas a hla de clase ii contra ras mutado | |
| CY1122720T1 (el) | Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii | |
| MX2017006865A (es) | Receptores de células t de kras anti-mutado. | |
| SA518391109B1 (ar) | Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ | |
| CY1122790T1 (el) | Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις | |
| MX2020005765A (es) | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. | |
| MX2020003504A (es) | Receptores de celulas t que reconocen p53 mutado. | |
| CL2022003264A1 (es) | Péptidos y sus combinaciones para uso en inmunoterapia contra el cáncer de próstata y otros | |
| CY1124176T1 (el) | Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων | |
| CY1118072T1 (el) | Συζευγματα cc-1065 αναλογων και διλειτουργικων αρθρωτων | |
| CO2018013471A2 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| EA202090931A3 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| PH12018501335A1 (en) | Novel generation of antigen-specific tcrs | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| CY1123520T1 (el) | Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια | |
| CL2021002491A1 (es) | Receptores de células t mage a4 | |
| CL2022002208A1 (es) | Receptor de células t restringido por hla de la clase i contra ras con mutación | |
| TR201905447T4 (tr) | Yeni mhc bağımsız tümörle ilişkili antijenler. | |
| CY1125328T1 (el) | Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων | |
| EA201990543A1 (ru) | Композиции и способы репрограммирования т-клеточных рецепторов с помощью гибридных белков | |
| AR109345A1 (es) | Receptores de linfocitos t e inmunoterapia basada en el uso de los mismos |